Alnylam initiates Phase II research with ALN-TTRsc for treatment of ATTR Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, announced today that it offers initiated a pilot Stage II study with ALN-TTRsc, a subcutaneously shipped RNAi therapeutic targeting the transthyretin gene in advancement for the treatment of TTR-mediated amyloidosis health issue . The Phase II trial, which is now open for enrollment, is aimed at analyzing the tolerability and preliminary medical activity of ALN-TTRsc in TTR cardiac amyloidosis sufferers with familial amyloidotic cardiomyopathy – which is due to autosomal dominant mutations in the TTR gene, or senile systemic amyloidosis – which is caused by idiopathic accumulation of wild-type TTR in the center.

colchicine and gout

Also in Global Wellness News: WHO highlights wellness care-associated infections; Niger meals shortages, healthcare workers; Latin American food security WHO Highlights Health Care-Associated Infection Prevention The WHO on Thursday highlighted the need for hands washing and other efforts to avoid health care-associated infections , which affect thousands of people annually, with developing countries carrying the best burden of such infections, CIDRAP News reviews . As part of its WHO SAVE LIVES: Clean THE HANDS campaign, the agency released an acknowledged fact sheet on HAIs; a written report , titled Survey on the responsibility of Endemic Wellness Care-Associated Infection Worldwide: Clean Treatment is Safer Care ; and a listing of websites from around the world promoting the campaign .